179 related articles for article (PubMed ID: 10741403)
1. The type II decoy receptor of IL-1 inhibits murine collagen-induced arthritis.
Bessis N; Guéry L; Mantovani A; Vecchi A; Sims JE; Fradelizi D; Boissier MC
Eur J Immunol; 2000 Mar; 30(3):867-75. PubMed ID: 10741403
[TBL] [Abstract][Full Text] [Related]
2. Soluble interleukin-1 receptor accessory protein ameliorates collagen-induced arthritis by a different mode of action from that of interleukin-1 receptor antagonist.
Smeets RL; Joosten LA; Arntz OJ; Bennink MB; Takahashi N; Carlsen H; Martin MU; van den Berg WB; van de Loo FA
Arthritis Rheum; 2005 Jul; 52(7):2202-11. PubMed ID: 15986350
[TBL] [Abstract][Full Text] [Related]
3. Blockade of the interleukin-21/interleukin-21 receptor pathway ameliorates disease in animal models of rheumatoid arthritis.
Young DA; Hegen M; Ma HL; Whitters MJ; Albert LM; Lowe L; Senices M; Wu PW; Sibley B; Leathurby Y; Brown TP; Nickerson-Nutter C; Keith JC; Collins M
Arthritis Rheum; 2007 Apr; 56(4):1152-63. PubMed ID: 17393408
[TBL] [Abstract][Full Text] [Related]
4. The type II IL-1 receptor interacts with the IL-1 receptor accessory protein: a novel mechanism of regulation of IL-1 responsiveness.
Lang D; Knop J; Wesche H; Raffetseder U; Kurrle R; Boraschi D; Martin MU
J Immunol; 1998 Dec; 161(12):6871-7. PubMed ID: 9862719
[TBL] [Abstract][Full Text] [Related]
5. Regulated expression and release of the IL-1 decoy receptor in human mononuclear phagocytes.
Colotta F; Saccani S; Giri JG; Dower SK; Sims JE; Introna M; Mantovani A
J Immunol; 1996 Apr; 156(7):2534-41. PubMed ID: 8786316
[TBL] [Abstract][Full Text] [Related]
6. Amelioration of collagen-induced arthritis in DBA/1J mice by recombinant TSG-6, a tumor necrosis factor/interleukin-1-inducible protein.
Mindrescu C; Thorbecke GJ; Klein MJ; Vilcek J; Wisniewski HG
Arthritis Rheum; 2000 Dec; 43(12):2668-77. PubMed ID: 11145024
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of the soluble form of the interleukin-1 receptor accessory protein as an inhibitor of interleukin-1 in collagen-induced arthritis.
Smeets RL; van de Loo FA; Joosten LA; Arntz OJ; Bennink MB; Loesberg WA; Dmitriev IP; Curiel DT; Martin MU; van den Berg WB
Arthritis Rheum; 2003 Oct; 48(10):2949-58. PubMed ID: 14558102
[TBL] [Abstract][Full Text] [Related]
8. Expression and in vitro properties of guinea pig IL-5: comparison to human and murine orthologs.
Scott CW; Budzilowicz C; Hubbs SJ; Stein M; Sobotka-Briner C; Wilkins DE
Mediators Inflamm; 2000; 9(3-4):181-7. PubMed ID: 11132776
[TBL] [Abstract][Full Text] [Related]
9. Increased production of intracellular interleukin-1 receptor antagonist type I in the synovium of mice with collagen-induced arthritis: a possible role in the resolution of arthritis.
Gabay C; Marinova-Mutafchieva L; Williams RO; Gigley JP; Butler DM; Feldmann M; Arend WP
Arthritis Rheum; 2001 Feb; 44(2):451-62. PubMed ID: 11229477
[TBL] [Abstract][Full Text] [Related]
10. The combination of tumor necrosis factor alpha blockade with interleukin-1 and interleukin-17 blockade is more effective for controlling synovial inflammation and bone resorption in an ex vivo model.
Chabaud M; Miossec P
Arthritis Rheum; 2001 Jun; 44(6):1293-303. PubMed ID: 11407688
[TBL] [Abstract][Full Text] [Related]
11. Interactions between IL-32 and tumor necrosis factor alpha contribute to the exacerbation of immune-inflammatory diseases.
Shoda H; Fujio K; Yamaguchi Y; Okamoto A; Sawada T; Kochi Y; Yamamoto K
Arthritis Res Ther; 2006; 8(6):R166. PubMed ID: 17078892
[TBL] [Abstract][Full Text] [Related]
12. Transfected type II interleukin-1 receptor impairs responsiveness of human keratinocytes to interleukin-1.
Bossù P; Visconti U; Ruggiero P; Macchia G; Muda M; Bertini R; Bizzarri C; Colagrande A; Sabbatini V; Maurizi G
Am J Pathol; 1995 Dec; 147(6):1852-61. PubMed ID: 7495308
[TBL] [Abstract][Full Text] [Related]
13. Selectivity release of the type II decoy IL-1 receptor.
Orlando S; Polentarutti N; Mantovani A
Cytokine; 2000 Jul; 12(7):1001-6. PubMed ID: 10880245
[TBL] [Abstract][Full Text] [Related]
14. Attenuation of collagen-induced arthritis in mice by treatment with vector cells engineered to secrete interleukin-13.
Bessis N; Boissier MC; Ferrara P; Blankenstein T; Fradelizi D; Fournier C
Eur J Immunol; 1996 Oct; 26(10):2399-403. PubMed ID: 8898952
[TBL] [Abstract][Full Text] [Related]
15. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion.
Lubberts E; Koenders MI; Oppers-Walgreen B; van den Bersselaar L; Coenen-de Roo CJ; Joosten LA; van den Berg WB
Arthritis Rheum; 2004 Feb; 50(2):650-9. PubMed ID: 14872510
[TBL] [Abstract][Full Text] [Related]
16. Differential regulation of type I and type II interleukin-1 receptors in focal brain inflammation.
Docagne F; Campbell SJ; Bristow AF; Poole S; Vigues S; Guaza C; Perry VH; Anthony DC
Eur J Neurosci; 2005 Mar; 21(5):1205-14. PubMed ID: 15813930
[TBL] [Abstract][Full Text] [Related]
17. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: a comparative study using anti-TNFalpha, anti-IL-1alpha/beta and IL-1Ra.
Joosten LA; Helsen MM; van de Loo FA; van den Berg WB
Arthritis Rheum; 2008 Feb; 58(2 Suppl):S110-22. PubMed ID: 18240201
[TBL] [Abstract][Full Text] [Related]
18. Protective effects of IL-1Ra or vIL-10 gene transfer on a murine model of wear debris-induced osteolysis.
Yang SY; Wu B; Mayton L; Mukherjee P; Robbins PD; Evans CH; Wooley PH
Gene Ther; 2004 Mar; 11(5):483-91. PubMed ID: 14724688
[TBL] [Abstract][Full Text] [Related]
19. Anti-inflammatory effect of all-trans-retinoic acid in inflammatory arthritis.
Nozaki Y; Yamagata T; Sugiyama M; Ikoma S; Kinoshita K; Funauchi M
Clin Immunol; 2006 Jun; 119(3):272-9. PubMed ID: 16412693
[TBL] [Abstract][Full Text] [Related]
20. Adenoviral delivery of IL-1 receptor antagonist abrogates disease activity during the development of autoimmune arthritis in IL-1 receptor antagonist-deficient mice.
Hur W; Cho ML; Yoon SK; Kim SY; Ju JH; Jhun JY; Heo SB; Moon YM; Min SY; Park SH; Kim HY
Immunol Lett; 2006 Aug; 106(2):154-62. PubMed ID: 16793145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
